ralfinamide

Ralfinamide is a small molecule analgesic under development primarily for the treatment of neuropathic pain. It is being developed by Newron Pharmaceuticals and has reached phase III clinical trials for neuropathic pain in several countries. Ralfinamide exhibits a multimodal mechanism of action, acting as a mixed voltage-gated sodium channel blocker (notably including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. These combined actions contribute to its anti-nociceptive effects observed in animal models of inflammatory and neuropathic pain[1][2][4]. Development for other indications such as dental pain and inflammatory pain has been discontinued[2].

Other names

Priralfinamide